Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Reuters NewMedia - November 14, 2002
Cervical cancer grows so slowly that women have plenty of time to be tested and have any preventive treatment, the organization advised.
"The new guidelines will have a major impact on the number of women who are over-screened and over-treated," Dr. Mary Simmonds, national volunteer president of the American Cancer Society, said in a statement. "Because most cervical pre-cancers grow slowly, having a test every two to three years will find almost all cervical pre-cancers and cancers while they can be removed or treated successfully."
Cervical cancer affects nearly 500,000 worldwide every year. Detected early, it can be easily treated but it will kill an estimated 300,000 women this year, mostly in the developing world where screening is not routine.
In the United States, the American Cancer Society estimates that 13,000 women will develop cervical cancer this year, and about 4,100 women will die.
Cervical cancer is usually caused by the sexually transmitted human wart virus. Pre-cancerous changes can be detected with the Pap smear test, and suspect areas removed before cancer develops.
The new guidelines say testing every two to three years is usually sufficient for women older than 30 who have had several "clear" tests.
"A doctor may suggest getting the test more often if a woman has certain risk factors such as human immunodeficiency virus (HIV) infection or a weakened immune system. Women 70 years of age and older who have had three or more normal Pap test results and no abnormal results in the last 10 years may choose to stop cervical cancer screening," the society said in a statement.
The group also said a new test for the wart virus, if it is approved by the U.S. Food and Drug Administration, may be added to the guidelines.
021114
RE021113
Copyright © 2002 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .